Sprout Pharmaceuticals, Inc.

The US Food and Drug Administration is starting to post information to key drug databases on its website again after most of its public communications were halted 21 January. The Center for Drug Evalu

A drug company’s risk of receiving a promotion enforcement letter from the US Food and Drug Administration may increase with corporate mergers and acquisitions and a failure to clear away old advertis

The US Food and Drug Administration’s imminent action on Biogen Pharma and Eisai Co., Ltd. ’s Alzheimer’s drug aducanumab is bound to be controversial, regardless of whether the agency approves the

The US Food and Drug Administration’s decision to grant conditional approval to Biogen Pharma and Eisai Co., Ltd. ’s Alzheimer’s drug aducanumab has been met with mixed responses. Questions about t